CureVac Shares Cease Trading Following BioNTech Acquisition

CureVac NL0015436031

The publicly traded chapter for CureVac has officially closed. The biotechnology firm is no longer listed on any stock exchange, marking its conclusion as an independent public company. This follows the finalization of its acquisition by competitor BioNTech, which has now fully integrated CureVac's operations.

Public shareholders no longer hold any equity in CureVac following the transaction. The company's shares were suspended from trading on the Nasdaq ahead of market open today, with the Vienna Stock Exchange confirming that the final day of trading on its platform was yesterday.

BioNTech first announced the successful completion of the takeover on December 18, 2025. The offer, which involved an exchange of shares, achieved an acceptance rate of approximately 86.75%, including a subsequent acceptance period.

Minority shareholders who did not initially participate in the offer ultimately received the same consideration as those who did. However, this compensation was subject to a Dutch statutory dividend withholding tax. The effective tax rate applied was 3.01%, a figure influenced by tax-recognized capital components. Shareholders not tax-resident in the Netherlands may have been eligible for a refund, with the deadline for submitting such applications having passed on January 27.

Final Steps in the Delisting Process

CureVac has completed a post-offer reorganization. Through this process, CureVac N.V. was merged into CureVac Merger B.V., making BioNTech the sole owner of the operational business. With no remaining public shareholders, the basis for a stock market listing was eliminated.

The company has informed Nasdaq of the reorganization's completion and requested the filing of a "Notification of Removal from Listing" (Form 25) with the U.S. Securities and Exchange Commission (SEC). The formal delisting from Nasdaq is set to become effective on January 16.

Subsequent to the Form 25 taking effect, CureVac Merger B.V. intends to file a Form 15 with the SEC. This action seeks to terminate its registration under Section 12(g) of the Securities Exchange Act, which would also suspend all ongoing reporting obligations.

Key Milestones at a Glance:
* Post-Offer Reorganization: Completed
* Final Nasdaq Trading Day: Yesterday (trading suspended pre-market today)
* Final Vienna Trading Day: January 7
* Offer Acceptance Rate: ~86.75%